AUSTIN, Texas, Feb. 18, 2020 /PRNewswire-PRWeb/ -- In response to increased demand for its clinical trial expertise and services, hyperCORE International, the US-based integrated site network, is announcing the addition of 2 partners to provide additional capacity required for its rapid business growth. These include the addition of AGA Clinical Trials and Clinical Site Partners expanding hyperCORE's concentration in the Southeast US and South America (Ecuador). This increase in partnership grows the hyperCORE International integrated site network by 25% in the first year of existence.
Mark Lacy, of Benchmark Research and CEO of hyperCORE International says,
"hyperCORE is a truly collaborative network. I have known these newly added partners for years and their expertise and professionalism only serve to strengthen this idea. We are moving in a direction to change this industry, and CSP and AGA will help us achieve this goal."
This expansion is the first large step towards increased growth in 2020 to help further service hyperCORE International's CRO and Sponsor partnerships. Ana Marquez, of newly added Clinical Site Partners, states:
"hyperCORE sites are the gold standard and the cream of the crop of our industry; for this reason, all of us at Clinical Site Partners are extremely proud to join this elite group of sites. We have always considered hyperCORE leaders and their Sites exemplary to the rest of us in the clinical trial space. We look forward to pushing the envelope with these industry giants so that we may continue to innovate and implement best practices, while maintaining standards of excellence."
If you are interested in becoming a member of hyperCORE's expanding and exceptional network please contact Michael Casey Executive Director of hyperCORE via email at to begin the process [email protected]
About hyperCORE International:
Formed in 2019, hyperCORE International is a super network of highly experienced and awarded clinical research site/network companies. It is an industry leader, providing Phase I-IV clinical trial services with more than 90 active research sites across the globe. It is the second largest clinical research site organization in the world. Its' member companies have over 100 years of combined experience and completed more than 6,000 studies helping to evaluate thousands of new drugs and treatments in more than 60,000 patients. Each member operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices.
hyperCORE International is committed to the highest standard of research excellence with subject safety, data integrity, rapid study startup, competitive enrollment, and outstanding subject retention as top priorities. Its members have won numerous awards for performance, quality, and innovation.
Learn more at http://www.hyperCOREinternational.com
Executive Director hyperCOREInternational
SOURCE HYPERCORE INTERNATIONAL
SOURCE hyperCORE International